Status:
COMPLETED
Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis
Lead Sponsor:
Galderma R&D
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.
Detailed Description
Same as above.
Eligibility Criteria
Inclusion
- Moderate to severe psoriasis involving 3-20% of the body surface area
Exclusion
- Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® Spray or more than 100 grams per week of Taclonex® Ointment
- Subjects having psoriasis that involves the scalp, face, or groin
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT00437255
Start Date
August 1 2006
End Date
June 1 2007
Last Update
July 29 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Minnesota Clinical Study Center
Fridley, Minnesota, United States, 55432
2
DermResearch, Inc.
Austin, Texas, United States, 78759
3
J & S Studies, Inc.
Bryan, Texas, United States, 77802
4
Baylor Research Institute
Dallas, Texas, United States, 75230